Michael Callaghan has resigned from Vermillion’s board of directors, the company stated in a filing with the US Securities and Exchange Commission last week.
Callaghan was a member of the company’s audit and compensation committees. The company said he resigned for personal reasons and not as the result of any disagreement.
Invitrogen announced that it has named Mark Smedley, the firm’s global head of operations, to lead the integration team for its $6.7 billion acquisition of Applied Biosystems.
RXi Pharmaceuticals has appointed University of Massachusetts scientist Victor Ambros to its scientific advisory board. Ambros is best known for his work in discovering microRNA. He was a professor at Dartmouth College from 1992 to 2007, and before that he studied genetic pathways as a post-doctoral fellow at the Massachusetts Institute of Technology.